Australia's Sigma Unlikely To Be Saved By iNova Investors
This article was originally published in PharmAsia News
Executive Summary
Reports predicting Australia's financially troubled Sigma Pharmaceuticals might be bought and saved are being dashed by closer looks at possible suitors
You may also be interested in...
Priority Review Voucher Eligibility List Gains Three Tropical Diseases
US FDA adds brucellosis, opisthorchiasis and paragonimiasis to the list of qualifying diseases but declines to include clonorchiasis and coccidioidomycosis, finding a significant market in developed nations for treatments or vaccines addressing the two conditions.
Mallinckrodt’s Terlipressin Narrowly Clears US FDA Panel As Need For Liver Treatment Outweighs Safety Worries
Advisory committee votes 8-7 to recommend approval for terlipressin to treat HRS-1 but is critical of Mallinckrodt’s plan to mitigate the risk of respiratory failure.
ECHA Committee Stops Short Of Advising Derogation Or Deadline Extension For Cosmetic Microplastic Ban
Uncertainties related to leave-on cosmetics’ microplastic releases to the environment, and the costs industry would face in removing microplastic from such products, “do not allow for SEAC to conclude whether other options would be more appropriate than a ban,” the European Chemicals Agency’s Socio-Economic Analysis Committee says in a 1 July draft opinion.
Need a specific report? 1000+ reports available
Buy Reports